Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENURONE vs APTIOM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.
Adjunctive therapy in the treatment of partial seizures with or without secondary generalization,Off-label: refractory epilepsy, complex partial seizures
Adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Terminal elimination half-life ranges from 20 to 48 hours (mean ~32 hours). Steady-state achieved within 5-7 days.
Primarily hepatic metabolism via hydrolysis and conjugation; involves CYP450 enzymes (minor contribution). Metabolites are excreted in urine.
Primarily glucuronidation via UGT2B7; also metabolized by CYP3A4, CYP2C19, and CYP1A2 to a lesser extent.
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Primarily eliminated by hepatic metabolism, with approximately 95% excreted as metabolites in urine and <2% as unchanged drug. Fecal excretion accounts for about 5%.
Approximately 80-90% bound, primarily to serum albumin. The binding is saturable, which can lead to nonlinear pharmacokinetics at high doses.
Approximately 90% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.5-1.0 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding. Vd may be increased in epilepsy or with co-administration of other anticonvulsants.
Volume of distribution is approximately 1.3 L/kg, suggesting extensive distribution into tissues.
Oral bioavailability is approximately 90-100% based on absorption studies. Food does not significantly affect absorption.
Oral bioavailability is approximately 60% (range 53-68%).
No specific guidelines; use with caution in renal impairment. Monitor for toxicity.
Estimated creatinine clearance (Cr Cl) >50 m L/min: no adjustment. Cr Cl 30-50 m L/min: reduce maintenance dose by 50%; Cr Cl <30 m L/min and not on hemodialysis: not recommended. Hemodialysis: 50 mg once daily with supplement of 25 mg after dialysis.
Child-Pugh Class A: No adjustment; Class B: Reduce dose by 25-50%; Class C: Avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce maintenance dose by 50%; initiate at 50 mg once daily, titrate slowly. Child-Pugh Class C: contraindicated.
Children: 10-20 mg/kg/day orally in 2-3 divided doses; maximum 1.5 g/day.
Children (≥4 years): Initial 1.5 mg/kg/day orally divided twice daily; titrate weekly by increments of 1.5 mg/kg/day to a maintenance of 3-6 mg/kg/day twice daily. Maximum: 400 mg twice daily.
Initiate at low end of dosing range (500 mg/day) and titrate slowly; monitor for neurotoxicity.
No specific dose adjustment based on age alone. Dose selection should be cautious, reflecting higher frequency of decreased renal/hepatic function and concomitant disease or drug therapy. Consider creatinine clearance and titrate slowly.
Phenacemide may cause fatal hepatotoxicity and aplastic anemia. Patients must be closely monitored for signs of hepatic dysfunction and blood dyscrasias.
None
Hepatotoxicity: monitor liver function tests at baseline and periodically; discontinue if signs of hepatic injury. Aplastic anemia: advise patients to report unexplained bleeding, bruising, or signs of infection. Suicidal ideation: monitor for changes in mood or behavior. Withdrawal: do not discontinue abruptly.
Suicidal behavior and ideation,Angioedema,Anaphylaxis,Dermatological reactions including Stevens-Johnson syndrome,Decreased serum sodium,Dizziness and gait disturbance,Hepatic injury
History of liver disease or hepatic dysfunction. History of aplastic anemia or bone marrow depression. Hypersensitivity to phenacemide or other hydantoins. Concurrent use with other hepatotoxic drugs.
Known hypersensitivity to eslicarbazepine acetate or any oxcarbazepine derivative
No significant food interactions documented. Avoid alcohol entirely due to additive CNS depression and potential hepatotoxicity.
Take with or without food. No specific food interactions reported.
Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.
Pregnancy Category D. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of fetal antiepileptic drug syndrome (facial dysmorphism, growth retardation, neurodevelopmental delay). Neonatal hemorrhage due to vitamin K deficiency may occur.
Excreted into breast milk; M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects (e.g., sedation, poor feeding) in the infant.
Excreted in human milk. Milk-to-plasma ratio not established. Potential for serious adverse reactions in nursing infants (sedation, poor suckling). Use only if benefit outweighs risk; consider alternative anticonvulsants.
Due to increased clearance in pregnancy, monitor serum concentrations and adjust dose to maintain therapeutic levels; may require dose increases by 20-30%.
Pregnancy increases clearance of eslicarbazepine acetate by approximately 30-40% in the second and third trimesters. Dose may require up to 50-100% increase from baseline to maintain therapeutic levels. Postpartum clearance returns rapidly; reduce dose promptly to avoid toxicity.
Phenurone (phenacemide) is a last-line anticonvulsant due to high risk of hepatotoxicity and bone marrow suppression. Monitor LFTs and CBC monthly. Avoid in patients with liver disease or history of psychosis. Therapeutic drug monitoring: target serum phenacemide level 5-12 mcg/m L. May cause severe personality changes and suicidal ideation.
APTIOM (eslicarbazepine acetate) is a once-daily antiepileptic drug for partial-onset seizures. Monitor serum sodium, especially in elderly or those on concomitant hyponatremia-inducing drugs. Titrate to maintenance dose over 2 weeks. Avoid abrupt discontinuation. Contraindicated in second- or third-degree AV block.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report signs of liver injury (yellow skin/eyes, dark urine, abdominal pain) or blood dyscrasias (fever, sore throat, easy bruising) immediately.,Avoid alcohol completely while taking this medication.,May cause drowsiness or dizziness; avoid driving until you know how this drug affects you.,Use reliable contraception; phenacemide can harm a fetus and decrease effectiveness of hormonal contraceptives.,Do not stop abruptly; withdrawal can precipitate seizures.
Take exactly as prescribed once daily; do not crush or chew tablets.,Report symptoms of hyponatremia: nausea, headache, confusion, lethargy.,Do not stop abruptly; withdrawal may increase seizure frequency.,Avoid driving until effects on dizziness or somnolence are known.,Notify doctor if pregnant, planning pregnancy, or breastfeeding.,Use effective contraception as APTIOM may reduce hormonal contraceptive efficacy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENURONE vs APTIOM, answered by our medical review team.
PHENURONE is a Anticonvulsant that works by Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.. APTIOM is a Anticonvulsant that works by Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENURONE and APTIOM depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENURONE is: Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.. The standard adult dose of APTIOM is: Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENURONE and APTIOM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENURONE is classified as Category C. Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.. APTIOM is classified as Category C. Pregnancy Category D. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.